AR058584A1 - Derivados de metastina y uso de los mismos - Google Patents
Derivados de metastina y uso de los mismosInfo
- Publication number
- AR058584A1 AR058584A1 ARP060105651A ARP060105651A AR058584A1 AR 058584 A1 AR058584 A1 AR 058584A1 AR P060105651 A ARP060105651 A AR P060105651A AR P060105651 A ARP060105651 A AR P060105651A AR 058584 A1 AR058584 A1 AR 058584A1
- Authority
- AR
- Argentina
- Prior art keywords
- ala
- tyr
- optionally substituted
- activity
- pro
- Prior art date
Links
- -1 cyclopropancarbonyl Chemical group 0.000 abstract 21
- 230000000694 effects Effects 0.000 abstract 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 4
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 abstract 4
- 230000028327 secretion Effects 0.000 abstract 4
- 239000000126 substance Chemical group 0.000 abstract 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical group NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 abstract 2
- GZYFIMLSHBLMKF-UHFFFAOYSA-N ALBIZZIINE Chemical compound OC(=O)C(N)CNC(N)=O GZYFIMLSHBLMKF-UHFFFAOYSA-N 0.000 abstract 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical group C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000005907 cancer growth Effects 0.000 abstract 2
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 2
- 230000001456 gonadotroph Effects 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 150000002993 phenylalanine derivatives Chemical class 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 abstract 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 abstract 1
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical group OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical group OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical group CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical group NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical group OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical group C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical group OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 abstract 1
- 125000000240 D-tyrosyl group Chemical group N[C@@H](C(=O)*)CC1=CC=C(C=C1)O 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
- 102000013599 Kisspeptins Human genes 0.000 abstract 1
- 108010012048 Kisspeptins Proteins 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 abstract 1
- 125000002068 L-phenylalanino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001483 arginine derivatives Chemical class 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 238000001879 gelation Methods 0.000 abstract 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005370388 | 2005-12-22 | ||
| JP2006275843 | 2006-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058584A1 true AR058584A1 (es) | 2008-02-13 |
Family
ID=37846230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105651A AR058584A1 (es) | 2005-12-22 | 2006-12-20 | Derivados de metastina y uso de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7960348B2 (https=) |
| EP (1) | EP1963362B1 (https=) |
| JP (2) | JP4653840B2 (https=) |
| KR (1) | KR101368607B1 (https=) |
| AR (1) | AR058584A1 (https=) |
| AU (1) | AU2006328333B2 (https=) |
| BR (1) | BRPI0619399B8 (https=) |
| CA (1) | CA2634647C (https=) |
| CR (1) | CR10019A (https=) |
| CY (1) | CY1112353T1 (https=) |
| DK (1) | DK1963362T3 (https=) |
| ES (1) | ES2375038T3 (https=) |
| GE (1) | GEP20115356B (https=) |
| HR (1) | HRP20110851T1 (https=) |
| IL (1) | IL190888A (https=) |
| JO (1) | JO2799B1 (https=) |
| MA (1) | MA30060B1 (https=) |
| ME (1) | ME01015B (https=) |
| MY (1) | MY151967A (https=) |
| NO (1) | NO341879B1 (https=) |
| NZ (1) | NZ568322A (https=) |
| PE (1) | PE20071141A1 (https=) |
| PL (1) | PL1963362T3 (https=) |
| PT (1) | PT1963362E (https=) |
| RS (1) | RS52007B (https=) |
| RU (1) | RU2430107C2 (https=) |
| SI (1) | SI1963362T1 (https=) |
| TW (1) | TWI386417B (https=) |
| WO (1) | WO2007072997A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761680A (zh) | 2002-12-26 | 2006-04-19 | 武田药品工业株式会社 | 肿瘤迁移抑制素衍生物及其用途 |
| CA2518541C (en) | 2003-03-12 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Gonadal function improving agents |
| CA2571420A1 (en) | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JO3048B1 (ar) * | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
| EP2277900A4 (en) * | 2008-04-24 | 2011-08-03 | Takeda Pharmaceutical | METASTINE DERIVATIVE AND ITS USE |
| LT2314609T (lt) * | 2008-07-30 | 2017-04-10 | Takeda Pharmaceutical Company Limited | Metastino darinys ir jo panaudojimas |
| JP2012513982A (ja) | 2008-12-29 | 2012-06-21 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| CN102665690A (zh) * | 2009-12-22 | 2012-09-12 | 武田药品工业株式会社 | 缓释制剂 |
| CA2802209C (en) | 2010-06-25 | 2019-12-31 | Takeda Pharmaceutical Company Limited | Sustained-release formulation |
| EP2755690B1 (en) | 2011-08-04 | 2020-04-01 | Merck Sharp & Dohme B.V. | Kisspeptide-pentasaccharide conjugates |
| WO2014010614A1 (ja) | 2012-07-12 | 2014-01-16 | 武田薬品工業株式会社 | マイクロカプセル粉末の製造方法 |
| US10220069B2 (en) * | 2014-01-22 | 2019-03-05 | The Johns Hopkins University | Compositions and methods for treating diabetes |
| JP6253146B2 (ja) * | 2014-02-04 | 2017-12-27 | 国立大学法人山口大学 | 新規なペプチド誘導体及びこれを含有する医薬 |
| TWI778979B (zh) | 2016-09-30 | 2022-10-01 | 瑞士商麥歐文科學有限公司 | 治療女性不孕症之方法 |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| CN109206481B (zh) * | 2017-07-05 | 2023-08-18 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| WO2025217074A1 (en) * | 2024-04-08 | 2025-10-16 | Radionetics Oncology, Inc. | Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
| MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
| CN1200114A (zh) | 1995-10-19 | 1998-11-25 | 武田药品工业株式会社 | 作为gnrh拮抗剂的喹啉衍生物 |
| JP2000510453A (ja) | 1996-04-19 | 2000-08-15 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン遊離特性を有する化合物 |
| WO1998039448A2 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP4486187B2 (ja) | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| PL353057A1 (en) | 1999-06-28 | 2003-10-06 | Basf Aktiengesellschaft | Method for preventing tumoral growth |
| CA2380613C (en) | 1999-08-02 | 2014-03-25 | Archer-Daniels-Midland Company | Production of l-lysine by corynebacterium strain having mutation in ilvbn operon |
| CN1411509A (zh) | 1999-12-17 | 2003-04-16 | 武田药品工业株式会社 | Kiss－1肽的制造方法 |
| JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| AU2001244609A1 (en) | 2000-03-30 | 2001-10-15 | Takeda Chemical Industries Ltd. | Novel protein, dna thereof and process for producing the same |
| US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
| JP2002320496A (ja) | 2001-02-26 | 2002-11-05 | Takeda Chem Ind Ltd | 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ |
| WO2002085399A1 (fr) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| KR100599419B1 (ko) | 2001-05-17 | 2006-07-10 | 가부시키가이샤 시마즈세이사쿠쇼 | 펩티드의 제조법 |
| US7112662B2 (en) | 2001-09-19 | 2006-09-26 | Takeda Pharmaceutical Company Limited | Anti-metasin antibodies and their methods of use |
| WO2003060125A1 (fr) | 2002-01-11 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Procede de production du peptide kiss-1 |
| JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
| DE60327344D1 (de) | 2002-10-25 | 2009-06-04 | Takeda Pharmaceutical | Gpr54 'knock-out' säugetiere und screening-verfahren, die sie verwenden |
| JP4804714B2 (ja) | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| CN1761680A (zh) | 2002-12-26 | 2006-04-19 | 武田药品工业株式会社 | 肿瘤迁移抑制素衍生物及其用途 |
| US6800611B2 (en) * | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
| KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Ｌｋ8 단백질을 유효성분으로 포함하는 항암제 |
| CA2518541C (en) * | 2003-03-12 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Gonadal function improving agents |
| EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| EP1618384A2 (en) | 2003-04-28 | 2006-01-25 | Wyeth | Methods utilising g-protein coupled receptor 54 |
| WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
| EP1633702B1 (en) | 2003-05-30 | 2008-07-02 | Prozymex A/S | Protease inhibitors |
| EP1688498B1 (en) | 2003-11-03 | 2011-03-09 | Beijing Sunbio Biotech Co., Ltd. | A recombinant protein with cancer suppression action, its encoding gene and use |
| RU2333221C2 (ru) | 2003-11-03 | 2008-09-10 | Бейцзин Санбио Байотек Ко., Лтд. | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение |
| WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
| CA2571420A1 (en) * | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US7725869B1 (en) | 2005-04-07 | 2010-05-25 | Xilinx, Inc. | Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description |
| WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| US20090099334A1 (en) | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090093615A1 (en) | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
-
2006
- 2006-12-20 AR ARP060105651A patent/AR058584A1/es active IP Right Grant
- 2006-12-20 TW TW095147852A patent/TWI386417B/zh active
- 2006-12-21 RS RS20110437A patent/RS52007B/sr unknown
- 2006-12-21 BR BRPI0619399A patent/BRPI0619399B8/pt not_active IP Right Cessation
- 2006-12-21 WO PCT/JP2006/326176 patent/WO2007072997A1/en not_active Ceased
- 2006-12-21 PT PT06843555T patent/PT1963362E/pt unknown
- 2006-12-21 SI SI200631152T patent/SI1963362T1/sl unknown
- 2006-12-21 ME MEP-2009-175A patent/ME01015B/me unknown
- 2006-12-21 RU RU2008125063/04A patent/RU2430107C2/ru active
- 2006-12-21 JP JP2008529406A patent/JP4653840B2/ja not_active Expired - Fee Related
- 2006-12-21 AU AU2006328333A patent/AU2006328333B2/en not_active Ceased
- 2006-12-21 DK DK06843555.1T patent/DK1963362T3/da active
- 2006-12-21 PL PL06843555T patent/PL1963362T3/pl unknown
- 2006-12-21 PE PE2006001686A patent/PE20071141A1/es active IP Right Grant
- 2006-12-21 US US12/158,251 patent/US7960348B2/en active Active
- 2006-12-21 HR HR20110851T patent/HRP20110851T1/hr unknown
- 2006-12-21 NZ NZ568322A patent/NZ568322A/en unknown
- 2006-12-21 MY MYPI20082169 patent/MY151967A/en unknown
- 2006-12-21 ES ES06843555T patent/ES2375038T3/es active Active
- 2006-12-21 CA CA2634647A patent/CA2634647C/en active Active
- 2006-12-21 EP EP06843555A patent/EP1963362B1/en active Active
- 2006-12-21 GE GEAP200610770A patent/GEP20115356B/en unknown
- 2006-12-21 JO JO2006486A patent/JO2799B1/en active
- 2006-12-21 KR KR1020087012506A patent/KR101368607B1/ko active Active
-
2008
- 2008-04-15 IL IL190888A patent/IL190888A/en active IP Right Grant
- 2008-05-26 CR CR10019A patent/CR10019A/es unknown
- 2008-06-10 NO NO20082595A patent/NO341879B1/no unknown
- 2008-06-18 MA MA31044A patent/MA30060B1/fr unknown
-
2010
- 2010-08-17 JP JP2010182482A patent/JP5298087B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-18 CY CY20111101116T patent/CY1112353T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058584A1 (es) | Derivados de metastina y uso de los mismos | |
| JP2010507565A5 (https=) | ||
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| NZ600732A (en) | Oxyntomodulin peptide analogue | |
| CN103755786A (zh) | 黑皮质素受体配体 | |
| DK148905B (da) | Analogifremgangsmaade til fremstilling af lh-rh-analoge nonapeptidderivater | |
| US20040254338A1 (en) | Melanin-concentrating hormone antagonists | |
| CN117050146B (zh) | 透明质酸修饰的美容肽、制备方法及其用途 | |
| JP2015516983A5 (https=) | ||
| US6627609B1 (en) | LHRH antagonists having improved solubility properties | |
| US5854216A (en) | Marker for growth hormone-releasing factor receptors | |
| JP2024511214A5 (https=) | ||
| WO2024235070A1 (zh) | 一种肽类化合物、组合物及其应用 | |
| Boyle et al. | Structure‐activity studies on prolactin‐releasing peptide (PrRP). Analogues of PrRP‐(19–31)‐peptide | |
| ES2123556T3 (es) | Peptidos de tipo bradiquinina. | |
| US4652627A (en) | Calcitonin analogs with C-terminal D-amino acid substituents | |
| Lebl et al. | Melanin concentrating hormone analogs: contraction of the cyclic structure. 1. Agonist activity | |
| Musso et al. | Development of helix-based vasoactive intestinal peptide analogues: identification of residues required for receptor interaction | |
| ES2541364T3 (es) | Péptido | |
| Bapst et al. | Dimeric DOTA-α-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity | |
| Pelton et al. | The role of the disulphide bonds in endothelin‐1 | |
| Ahmed et al. | Importance of the C‐terminal phenylalanine of gastrin for binding to the human CCK2 receptor | |
| US20040147432A1 (en) | Melanin-concentrating hormone analogs | |
| Taylor et al. | Delivery of bioactive, gel‐isolated proteins into live cells | |
| Semmes et al. | Substitution of norleucine for methionine residues in a crustacean pigment-dispersing hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |